250 related articles for article (PubMed ID: 27494876)
21. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
22. Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance.
Hu J; Xia X; Zhao Q; Li S
Cancer Lett; 2021 Apr; 502():143-153. PubMed ID: 33279621
[TBL] [Abstract][Full Text] [Related]
23. Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand.
Nakamura K; Nakayama M; Kawano M; Amagai R; Ishii T; Harigae H; Ogasawara K
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9421-6. PubMed ID: 23690625
[TBL] [Abstract][Full Text] [Related]
24. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.
Zingoni A; Cecere F; Vulpis E; Fionda C; Molfetta R; Soriani A; Petrucci MT; Ricciardi MR; Fuerst D; Amendola MG; Mytilineos J; Cerboni C; Paolini R; Cippitelli M; Santoni A
J Immunol; 2015 Jul; 195(2):736-48. PubMed ID: 26071561
[TBL] [Abstract][Full Text] [Related]
25. RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.
Lam AR; Bert NL; Ho SS; Shen YJ; Tang LF; Xiong GM; Croxford JL; Koo CX; Ishii KJ; Akira S; Raulet DH; Gasser S
Cancer Res; 2014 Apr; 74(8):2193-2203. PubMed ID: 24590060
[TBL] [Abstract][Full Text] [Related]
26. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
27. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
[TBL] [Abstract][Full Text] [Related]
28. Increased susceptibility to liver injury in hepatitis B virus transgenic mice involves NKG2D-ligand interaction and natural killer cells.
Chen Y; Wei H; Sun R; Dong Z; Zhang J; Tian Z
Hepatology; 2007 Sep; 46(3):706-15. PubMed ID: 17626270
[TBL] [Abstract][Full Text] [Related]
29. Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models.
Konagai A; Yoshimura K; Hazama S; Yamamoto N; Aoki K; Ueno T; Fujioka M; Iijima H; Kato M; Uchida M; Wada T; Inoue M; Asao T; Fuse M; Wada S; Kuramasu A; Kamei R; Takeda S; Yamamoto S; Yoshino S; Oka M; Nagano H
Anticancer Res; 2017 Aug; 37(8):4093-4101. PubMed ID: 28739693
[TBL] [Abstract][Full Text] [Related]
30. Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.
Bedel R; Thiery-Vuillemin A; Grandclement C; Balland J; Remy-Martin JP; Kantelip B; Pallandre JR; Pivot X; Ferrand C; Tiberghien P; Borg C
Cancer Res; 2011 Mar; 71(5):1615-26. PubMed ID: 21257710
[TBL] [Abstract][Full Text] [Related]
31. Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Xuan XY; Zhang JF; Hu GM; Li QR; Liu PP; Du Y
Cancer Gene Ther; 2015 Jul; 22(7):368-74. PubMed ID: 26113176
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic Citrate Flux Modulates the Immune Stimulatory NKG2D Ligand MICA in Cancer Cells.
Møller SH; Mellergaard M; Madsen M; Bermejo AV; Jepsen SD; Hansen MH; Høgh RI; Aldana BI; Desler C; Rasmussen LJ; Sustarsic EG; Gerhart-Hines Z; Daskalaki E; Wheelock CE; Hiron TK; Lin D; O'Callaghan CA; Wandall HH; Andresen L; Skov S
Front Immunol; 2020; 11():1968. PubMed ID: 32849657
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells.
Ferrari de Andrade L; Kumar S; Luoma AM; Ito Y; Alves da Silva PH; Pan D; Pyrdol JW; Yoon CH; Wucherpfennig KW
Cancer Immunol Res; 2020 Jun; 8(6):769-780. PubMed ID: 32209637
[TBL] [Abstract][Full Text] [Related]
34. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D.
Song H; Park H; Park G; Kim YS; Lee HK; Jin DH; Kang HS; Cho DH; Hur D
Oncol Rep; 2014 Jul; 32(1):425-30. PubMed ID: 24841552
[TBL] [Abstract][Full Text] [Related]
35. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
[TBL] [Abstract][Full Text] [Related]
36. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
37. Intact NKG2D-independent function of NK cells chronically stimulated with the NKG2D ligand Rae-1.
Champsaur M; Beilke JN; Ogasawara K; Koszinowski UH; Jonjic S; Lanier LL
J Immunol; 2010 Jul; 185(1):157-65. PubMed ID: 20530257
[TBL] [Abstract][Full Text] [Related]
38. Human fused NKG2D-IL-15 protein controls xenografted human gastric cancer through the recruitment and activation of NK cells.
Chen Y; Chen B; Yang T; Xiao W; Qian L; Ding Y; Ji M; Ge X; Gong W
Cell Mol Immunol; 2017 Mar; 14(3):293-307. PubMed ID: 26364916
[TBL] [Abstract][Full Text] [Related]
39. VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer.
Xie W; Liu F; Wang Y; Ren X; Wang T; Chen Z; Tang M; Sun F; Li Z; Wang M; Zhang J
Oncotarget; 2016 Mar; 7(13):16445-61. PubMed ID: 26909862
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
